Codexis to Report First Quarter 2025 Financial Results on May 14

Rhea-AI Summary

Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutics manufacturing, has scheduled its first quarter 2025 financial results announcement for May 14, 2025, after market close.

The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss financial performance and provide business updates. Investors can access the live webcast through the Codexis Investor Relations website, where it will remain available for 90 days.

For those preferring telephone access, the live call can be joined by dialing:

• Domestic: 877-705-2976
• International: 201-689-8798

A 48-hour telephone replay will be available using:

• Domestic: 877-660-6853
• International: 201-612-7415
• Access ID: 13726635

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first quarter of 2025 on Wednesday, May 14, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.

Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.

About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver^® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.

For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com

FAQ

When will Codexis (CDXS) release Q1 2025 earnings?

Codexis (CDXS) will release its first quarter 2025 earnings on Wednesday, May 14, 2025, after market close.

How can investors join Codexis Q1 2025 earnings call?

Investors can join by dialing 877-705-2976 (domestic) or 201-689-8798 (international), or access the live webcast through the Codexis Investor Relations website.

What time is Codexis (CDXS) earnings call on May 14, 2025?

Codexis will host its earnings conference call and webcast at 4:30 pm Eastern Time on May 14, 2025.

How long will Codexis Q1 2025 earnings webcast be available?

The earnings webcast will be archived on the Codexis Investor Relations website for 90 days after the call.

How can I access Codexis Q1 2025 earnings call replay?

The earnings call replay will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international) with access ID #13726635.